Skip to main content
Clinical Trials/IRCT2014052417811N2
IRCT2014052417811N2
Completed
Phase 3

The Effect of Fluxetine on Disease Clinical & Radiologic activity of Multiple sclerosis

Arak University of Medical Science,Office of Vice Chancellor for Research0 sites58 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
multiple sclerosis.
Sponsor
Arak University of Medical Science,Office of Vice Chancellor for Research
Enrollment
58
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Arak University of Medical Science,Office of Vice Chancellor for Research

Eligibility Criteria

Inclusion Criteria

  • inclusion criteria: age 18–50 years? ?clinically definitive relapsing remitting MS((according to the 2005 revised McDonald criteria)confirmed by a neurologist ? Additional inclusion criteria were an Expanded disability Status Score (EDSS) of less or equal to 5\.5 ?
  • exclusion criteria: progressive forms of multiple sclerosis ? an onset of relapse or receipt of any glucocorticoid treatment during trial period ? use of immunomodulatory, immunosuppressive, IVIg or plasmapherasis or antidepressant drugs in the previous 6 months? the use of corticosteroids in the previous 8 weeks ? depression defined as a score of 19 or higher on Beck’s Depression Inventory II ?contraindication to MRI ? other neurological or systemic disorder that would interfere with the assessments ? pregnancy or unwillingness to use acceptable birth control.
  • severe suicidality including ideation, plan, and intentclinically significant ? unstable medical or surgical conditions that would preclude safe and complete participation in the study.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials